Our Leadership Team
|
Pascal Druzgala, PhD
Co-founder, Director, and Chief Scientific Officer Dr. Pascal Druzgala is a co-founder, member of the board of managers and CSO of Renexxion. He has more than twenty years of experience as a CSO in previous positions at Armetheon, Optivia Biotechnology, and ARYx Therapeutics (NASDAQ:ARYX), where he served as senior VP and CSO from 1997 to 2011, as well as chairman of the scientific advisory board.
Dr. Druzgala received a Pharm.D. degree from the University of Montpellier, France, and then went on to earn a diplôme d’études approfondies degree (DEA) at the European Institute of Industrial Pharmaceutical Sciences (IPIM), also in Montpellier, France. Dr. Druzgala later graduated in 1985 from the University of Florida with a doctorate in medicinal chemistry. He completed his post-doctorate work at the Center for Drug Design and Discovery at the University of Florida, where he first experimented with various drug discovery programs utilizing retrometabolic techniques. These techniques, pioneered in the late 1970s, are the basis for the enhanced safety of drugs discovered and developed under Dr Druzgala’s leadership, including Renexxion’s clinical-stage drug naronapride. |